Concepedia

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

Xinyue Lv, Huiguo Ding, Jun-Fu Zheng, Chunlei Fan, Lei Li

World Journal of Gastroenterology · 2020 · 41 citations · 30 references

DOIFull text

Open access

Abstract

Rifaximin mitigates ascites and improves survival of cirrhotic patients with refractory ascites. A possible mechanism is that rifaximin regulates the structure and function of intestinal bacteria, thus improving the systemic inflammatory state.

References

30

Alterations of the human gut microbiome in liver cirrhosis

Nan Qin, Fengling Yang, Ang Li et al. · Nature · 2014 · 2.2K citations

, , +9

Characterization of fecal microbial communities in patients with liver cirrhosis

Yanfei Chen, Fengling Yang, Haifeng Lu et al. · Hepatology · 2011 · 1K citations · Full text

Hepatic encephalopathy

Andrés T. Blei, Juan Córdoba · The American Journal of Gastroenterology · 2001 · 524 citations

, , +9

Microbial butyrate and its role for barrier function in the gastrointestinal tract

Svenja Plöger, Friederike Stumpff, G.B. Penner et al. · Annals of the New York Academy of Sciences · 2012 · 436 citations

, , +27

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Jasmohan S. Bajaj, Douglas M. Heuman, Arun J. Sanyal et al. · PLoS ONE · 2013 · 411 citations · Full text